Your privacy is very important to us. When you visit our website, please agree to the use of all cookies. For more information about personal data processing, please go to Privacy Policy.
NSR｜HuidaGene's Yang Hui team pioneers disruptive guanine (G) base editor
recommendations
-
Sep 06,2023
HuidaGene Therapeutics Announces First Patient Dosed Of The World's First Novel CRISPR/Cas13 RNA-Editing Therapy HG202 For Neovascular Age-related Macular Degeneration
-
Dec 19,2023
HuidaGene Announces Rare Pediatric Drug Designation Granted to HG302, A Novel CRISPR DNA-editing Therapy, for the Treatment of Duchenne Muscular Dystrophy
-
Aug 04,2023
HuidaGene and Kactus Announce Strategic Collaboration and License Agreement to Promote Commercialization of Next-Generation Gene Editing Enzyme, hfCas12Max®
-
Aug 07,2023
HuidaGene Therapeutics Receives FDA Rare Pediatric Disease Designation for HG004 to Treat Inherited Blindness